Soft Coral Eunicellin Compounds for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases related to inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), such as atherosclerosis and neuropathic pain, are inadequate due to side effects and limited efficacy of existing non-steroidal anti-inflammatory drugs (NSAIDs), and there is a need for novel compounds that can effectively inhibit these inflammatory proteins.
Innovation Solution
Isolation of novel eunicellin compounds from the soft coral Klyxum simplex, which can be used to inhibit iNOS and COX-2, thereby treating associated diseases, through extraction and purification methods that minimize ecological impact by culturing the coral.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing NSAIDs are used to inhibit iNOS and COX-2, then inflammation-related diseases can be treated, but side effects increase and efficacy is limited
Solution Approach 1:
The patent extracts and isolates specific bioactive compounds (eunicellins-1, -2, and -3) from the soft coral Klyxum simplex. This extraction process identifies and separates the effective anti-inflammatory components from the complex natural source, providing purified compounds with defined structures that can be used therapeutically without the limitations of crude extracts or existing synthetic NSAIDs
Solution Approach 2:
The patent creates synthetic or semi-synthetic copies of the naturally occurring eunicellin compounds. By replicating the molecular structures of eunicellins-1, -2, and -3, the invention produces pharmaceutical agents that mimic the beneficial anti-inflammatory effects of the natural compounds while allowing for controlled production and dosage standardization
2Quantity of substance
If soft coral is collected from natural habitats, then compounds can be obtained, but ecological damage occurs
Solution Approach 1:
The patent establishes cultured populations of the soft coral Klyxum simplex as a preliminary resource base before compound extraction is needed. By maintaining coral cultures in controlled environments, the invention ensures a renewable source of eunicellin compounds that does not require harvesting from wild populations, thus preventing ecological damage while ensuring adequate material supply
Solution Approach 2:
The patent utilizes the coral's own natural metabolic pathways to produce eunicellin compounds. By culturing the coral and allowing it to naturally synthesize these bioactive molecules, the system harnesses the organism's inherent biochemical capabilities to provide the desired pharmaceutical compounds without external intervention that would harm the ecosystem
Data Source
AI summary
The invention relates to compounds from the soft coral and the generation thereof. The invention also relates to the uses of the compounds from the soft coral in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2.